224 related articles for article (PubMed ID: 15487449)
21. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
22. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
23. [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance].
Xu MR; Chen Y; Zhou SR; Chi MM; Chen SL; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):356-60. PubMed ID: 19799084
[TBL] [Abstract][Full Text] [Related]
24. [Galectin-3 in diagnosis of thyroid cancer].
Semenov DIu; Pozharisskiĭ KM; Boriskova ME; Pankova PA; Mukhina MS; Feshchenko NS
Vopr Onkol; 2008; 54(3):321-3. PubMed ID: 18652236
[TBL] [Abstract][Full Text] [Related]
25. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
Wang SL; Li SH; Chen WT; Chai CY
APMIS; 2007 Aug; 115(8):906-10. PubMed ID: 17696946
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
27. [Low galectin-3 capacity to discriminate thyroid lesions].
De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
[TBL] [Abstract][Full Text] [Related]
28. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
29. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
Murphy KM; Chen F; Clark DP
Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
[TBL] [Abstract][Full Text] [Related]
30. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Chandan VS; Faquin WC; Wilbur DC; Khurana KK
Cancer; 2006 Oct; 108(5):331-6. PubMed ID: 16944537
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
32. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
Cvejic D; Savin S; Petrovic I; Selemetjev S; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2005 Sep; 27(3):210-4. PubMed ID: 16244583
[TBL] [Abstract][Full Text] [Related]
33. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
Scognamiglio T; Hyjek E; Kao J; Chen YT
Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067
[TBL] [Abstract][Full Text] [Related]
35. Galectin-3 expression in papillary microcarcinoma of the thyroid.
Cvejic D; Savin S; Petrovic I; Paunovic I; Tatic S; Krgovic K; Havelka M
Histopathology; 2005 Aug; 47(2):209-14. PubMed ID: 16045783
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
37. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?
Londero SC; Godballe C; Krogdahl A; Bastholt L; Specht L; Sørensen CH; Pedersen HB; Pedersen U; Christiansen P
Acta Oncol; 2008; 47(3):451-7. PubMed ID: 17906980
[TBL] [Abstract][Full Text] [Related]
38. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
40. Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors.
Kalfert D; Ludvikova M; Kholova I; Ludvik J; Topolocan O; Plzak J
Neoplasma; 2020 Jan; 67(1):164-170. PubMed ID: 31777257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
